Key Capital to Focus on Oral Pill Cancer Treatment Success
Crwe World,
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 …
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 …
advises the following to clarify the Company's corporate focus, direction, and progress.
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 …
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 …
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 …
NEW YORK, NY / ACCESSWIRE / March 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the following to clarify the…
advises that in association with its partner, global oral pill vaccine pioneer Immunitor, it will be launch a unique M.vaccae…
Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to…
*Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to…
*Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to…
Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to…
Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to…
Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to…
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and…
in response to recent global media coverage of a scramble or race to develop oral pill vaccines for disease treatment and/or…
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and…
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and…
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and…
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and…
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and…
Full Patent for Immunitor issued in China and EU Claims being re-filed NEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY…
advises that it continues to work with Immunitor, its partner and Licensor, to progress further research and development of its…
Full Patent for Immunitor issued in China and EU Claims being re-filed NEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY…
Full Patent for Immunitor issued in China and EU Claims being re-filedNEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY…
Full Patent for Immunitor issued in China and EU Claims being re-filedNEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY…
Key Capital to Launch its Promising Oral Pill Therapeutic which is to be Marketed as a Supplement NEW YORK, NY, UNITED STATES…
advises that as SARS-CoV-2 continues to spread, and reports of increases in daily infections, hospitalizations, and deaths are…
Promising Oral Pill Therapeutic Proposed to be Marketed as a Supplement NEW YORK, NY / ACCESSWIRE / January 28, 2021 / KEY…
Promising Oral Pill Therapeutic Proposed to be Marketed as a Supplement NEW YORK, NY / ACCESSWIRE / January 28, 2021 / KEY…
Promising Oral Pill Therapeutic Proposed to be Marketed as a Supplement NEW YORK, NY / ACCESSWIRE / January 28, 2021 / KEY…
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
*Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
*Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine…
/ KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear that the approach to global COVID-19…
/ KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear that the approach to global COVID-19…
/ KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear that the approach to global COVID-19…
NEW YORK, NY / ACCESSWIRE / January 6, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear…
/ KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear that the approach to global COVID-19…
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / December 28, 2020 / KEY…
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / December 28, 2020 / KEY…
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / December 28, 2020 / KEY…
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / December 28, 2020 / KEY…
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / December 28, 2020 / KEY…
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated NEW YORK, NY / ACCESSWIRE / December 1, 2020 / KEY…
*FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated* *NEW YORK, NY / ACCESSWIRE / December 1, 2020 / KEY…
*FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated* *NEW YORK, NY / ACCESSWIRE / December 1, 2020 / KEY…
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated NEW YORK, NY / ACCESSWIRE / December 1, 2020 / KEY…
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated NEW YORK, NY / ACCESSWIRE / December 1, 2020 / KEY…
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated NEW YORK, NY / ACCESSWIRE / December 1, 2020 / KEY…
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated NEW YORK, NY / ACCESSWIRE / December 1, 2020 / KEY…
FDA Orphan Drug Designated Immunitor V5 Development to be Accelerated Key Capital Corporation (OTCMKTS:KCPC) The sooner that we…
(GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises the Company has entered into an…
(GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises the Company has entered into an…
(GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- KEY CAPITAL CORPORATION (OTC Pink:KCPC) advises the Company has entered into an…
(GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- KEY CAPITAL CORPORATION (OTC:KCPC) advises the Company has entered into an agreement…
NewMediaWire 2017-06-01 SCOTTSDALE, AZ - (NewMediaWire) - June 1, 2017 - KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises the…
- KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises the Company is progressing partnerships with established and recognized…
SCOTTSDALE, AZ--(Marketwired - Jun 1, 2017) - KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises the Company is progressing…
- KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises the Company is progressing partnerships with established and recognized…
SCOTTSDALE, AZ -- (Marketwired) -- 06/01/17 -- KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises the Company is progressing…
- KEY CAPITAL CORPORATION (OTC PINK: KCPC ) advises the Company is progressing partnerships with established and recognized…
_ SCOTTSDALE, AZ -- (Marketwired) -- 06/01/17 -- KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises the Company is progressing…
SCOTTSDALE, AZ -- (Marketwired) -- 06/01/17 -- KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the Company is progressing…
Vancouver British Columbia (PRWEB) May 29 2017 At least 30 patients with inoperable and chemotherapy-failed pancreatic cancer…
PRWeb Published 7:00 am, Monday, May 29, 2017 Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy…
PRWeb Published 9:00 am, Monday, May 29, 2017 Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy…
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
PRWeb 2017-05-29 Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with…
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
We are glad to have opportunity to offer the most advanced immunotherapy available today for patients with pancreatic cancer…
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.
Immunitor Inc., is announcing the launch of Phase II, open-label, immunotherapy trial in patients with pancreatic cancer.